New cancer diagnostics can predict chemotherapy response in triple negative breast cancer
US researchers innovate cancer diagnostics using Kinase Inhibitor Pulldown Assay, or KIPA, to search for proteins they could target to control tumour growth.
List view / Grid view
US researchers innovate cancer diagnostics using Kinase Inhibitor Pulldown Assay, or KIPA, to search for proteins they could target to control tumour growth.
A combination of radiotherapy followed by immunotherapy is a promising strategy for the treatment of oral malignant melanomas in dogs.
Dr Andy Souers highlights the unwavering commitment to finding an enhanced therapeutic approach that eliminates the need for chemotherapy in blood cancer treatment. This transformative discovery represents a significant leap forward in the way we combat this complex disease, offering new hope to countless patients worldwide.
Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).
Scientist and doctors from Spain have uncovered that oxaliplatin, a chemotherapy drug used to treat colon and rectal cancer, avoids the side effects this treatment can have on normal tumour cells, including potential chemotherapy resistance
A new drug could replace the current standard for treating radioresistance brain cancer by sensitising the cancer cells to radiotherapy.
This article outlines three innovative studies that use nanotechnology to deliver a new immunotherapy approach towards cancers.
University of Pittsburgh researchers have designed cancer-fighting nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy
A new implant that combines internal radiation and chemotherapy dissolved tumours in mice across multiple models.
The scientists found the mechanism of drug resistance depends on activation of a protein called KDM1B which controls and regulates gene expression.
Researchers have shown that a synthetic IL-9 receptor allows T cells to fight against cancer without the need for chemotherapy or radiation.
For the first time, researchers have tested a molecule that combines three distinct technologies against glioblastoma, the most aggressive type of brain cancer.
Tested using a new brain tissue model, researchers have developed nanoparticles which may be able to deliver chemotherapy drugs for glioblastoma.
Researchers have found how ovarian cancer tumours defy immunotherapy, identifying new molecular targets that might boost immune response.
Research in mice has shown that adding anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumour growth.